References
- Trojano M, Pellegrini F, Paolicelli D et al. Real-life impact of early interferon-β therapy in relapsing multiple sclerosis. Ann. Neurol.66, 513–520 (2009).
- Hensiek AE, Sawcer SJ, Feakes R et al. HLA DR15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry72, 184–187 (2002).
- Montalbán X, Tintoré M, Swanton J et al. MRI criteria for MS in patients with clinically isolated síndromes. Neurology74, 1–8 (2010).
- Villar LM, García-Barragán N, Sádaba MC et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J. Neurol. Sci.266, 34–37 (2008).
- Stone LA, Smith ME, Albert PS et al. Blood–brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing–remitting multiple sclerosis: relationship to course, gender, and age. Neurology45, 1122–1126 (1995).
- Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch. Neurol.66, 54–59 (2009).
- Waubant E, Chabas D, Okuda DT et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch. Neurol.66, 967–971 (2009).
- Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bö L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338, 278–285 (1998).
- Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain126, 770–782 (2003).
- Brex PA, Ciccarelli O, O’Riordan JI, SailerM, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med.346, 158–164 (2002).
- Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology73, 1616–1623 (2009).
- Coles AJ, Cox A, Le Page E et al. The window of therapeutic opportunity in multiple sclerosis. Evidence from monoclonal antibody therapy. J. Neurol.253, 98–108 (2006).
- Li DK, Zhao GJ, Paty DW et al. Randomized controlled trial of interferon-β-1a in secondary progressive MS: MRI results. Neurology56, 1505–1513 (2001).
- Kappos L, Traboulsee A, Constantinescu C et al. Long-term subcutaneous interferon β-1a therapy in patients with relapsing–remitting MS. Neurology67, 944–953 (2006).
- Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet370, 389–397 (2007).